Compass Therapeutics Inc (CMPX)

$4.87 +0.02 (0.41%)
Market Cap 862.63M
Revenue (ttm) 850,000.00
Net Income (ttm) -49.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,809.41%
Debt to Equity Ratio 0.00
Volume 2,511,300
Avg Vol 1,881,124
Day's Range N/A - N/A
Shares Out 177.86M
Stochastic %K 73%
Beta 1.48
Analysts Strong Sell
Price Target $12.73

Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8099
Address:
80 Guest Street, Suite 601, Boston, United States
Iightning
Iightning Nov. 22 at 12:33 AM
1ightning® Options Trade Alert (Actionable) | Buy $CMPX Dec 19 $5 Call | Enter: $0.52 Exit: $0.98 | Profit: 86.05% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 21 at 3:53 AM
1ightning® Options Trade Alert (Actionable) | Buy $CMPX Dec 19 $5 Call | Enter: $0.52 Exit: $0.98 | Profit: 86.05% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 20 at 1:20 AM
1ightning® Options Trade Alert (Actionable) | Buy $CMPX Dec 19 $5 Call | Enter: $0.52 Exit: $0.98 | Profit: 86.05% ROI | https://1ightning.com
0 · Reply
Lexcol
Lexcol Nov. 19 at 3:44 PM
$CMPX
0 · Reply
Iightning
Iightning Nov. 19 at 9:29 AM
1ightning® Options Trade Alert (Actionable) | Buy $CMPX Dec 19 $5 Call | Enter: $0.52 Exit: $0.98 | Profit: 86.05% ROI | https://1ightning.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 16 at 11:09 PM
$CMPX $CNBS $COF $COHR $COIN
1 · Reply
Marvinvaca
Marvinvaca Nov. 15 at 12:00 PM
$CMPX https://youtu.be/P7TnHzJ6_20?si=Wq209zn6G416N8SW
0 · Reply
Lexcol
Lexcol Nov. 12 at 3:13 PM
$CMPX $OCGN
0 · Reply
Lexcol
Lexcol Nov. 12 at 1:59 PM
$CMPX 5$ today
0 · Reply
Lexcol
Lexcol Nov. 11 at 8:59 PM
$OCGN $CMPX
0 · Reply
Latest News on CMPX
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:30 AM EST - 16 days ago

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 4, 2025, 9:00 AM EST - 17 days ago

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Compass Therapeutics to Participate in Upcoming November Investor Events

Nov 3, 2025, 8:00 AM EST - 18 days ago

Compass Therapeutics to Participate in Upcoming November Investor Events

Compass Therapeutics, Inc. (CMPX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 2:06 AM EDT - 2 months ago

Compass Therapeutics, Inc. (CMPX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Compass Therapeutics to Participate in Upcoming September Investor Events

Aug 26, 2025, 8:00 AM EDT - 3 months ago

Compass Therapeutics to Participate in Upcoming September Investor Events

Compass Therapeutics: Finding Their Way With More Positive Updates In BTC

Aug 13, 2025, 9:40 AM EDT - 3 months ago

Compass Therapeutics: Finding Their Way With More Positive Updates In BTC

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

Aug 12, 2025, 10:28 PM EDT - 3 months ago

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

Compass Therapeutics Announces Proposed Public Offering

Aug 12, 2025, 4:01 PM EDT - 3 months ago

Compass Therapeutics Announces Proposed Public Offering

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Aug 11, 2025, 7:00 AM EDT - 3 months ago

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

Aug 8, 2025, 4:01 PM EDT - 3 months ago

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 6 months ago

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers

May 12, 2025, 9:51 PM EDT - 6 months ago

Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 7 months ago

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in Upcoming May Investor Events

May 6, 2025, 8:00 AM EDT - 7 months ago

Compass Therapeutics to Participate in Upcoming May Investor Events

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 7 months ago

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

Apr 21, 2025, 8:00 AM EDT - 7 months ago

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Apr 2, 2025, 4:05 PM EDT - 8 months ago

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Apr 1, 2025, 7:00 AM EDT - 8 months ago

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Mar 31, 2025, 4:05 PM EDT - 8 months ago

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 8:00 AM EST - 9 months ago

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Dec 10, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer

Dec 9, 2024, 12:54 PM EST - 1 year ago

Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Compass Therapeutics to Participate in Upcoming Investor Events

Nov 13, 2024, 8:30 AM EST - 1 year ago

Compass Therapeutics to Participate in Upcoming Investor Events

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Nov 12, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 8, 2024, 10:05 AM EST - 1 year ago

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 10:31 AM EDT - 1 year ago

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

Compass Therapeutics: Pointing Right At Some Tough Cancers

Jun 20, 2024, 3:14 AM EDT - 1 year ago

Compass Therapeutics: Pointing Right At Some Tough Cancers

Compass Therapeutics Announces CEO Transition

May 28, 2024, 4:10 PM EDT - 1 year ago

Compass Therapeutics Announces CEO Transition

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

May 23, 2024, 5:05 PM EDT - 1 year ago

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

May 13, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 9, 2024, 12:00 PM EDT - 1 year ago

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Mar 21, 2024, 9:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Compass Therapeutics Provides Corporate Update

Jan 5, 2024, 8:00 AM EST - 2 years ago

Compass Therapeutics Provides Corporate Update

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 7:30 AM EST - 2 years ago

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

Jun 22, 2023, 4:05 PM EDT - 2 years ago

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

May 4, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Apr 19, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 15, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Feb 2, 2023, 8:30 AM EST - 3 years ago

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023

Jan 19, 2023, 5:00 PM EST - 3 years ago

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

Jan 6, 2023, 8:30 AM EST - 3 years ago

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21

Dec 15, 2022, 8:30 AM EST - 3 years ago

Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21

Iightning
Iightning Nov. 22 at 12:33 AM
1ightning® Options Trade Alert (Actionable) | Buy $CMPX Dec 19 $5 Call | Enter: $0.52 Exit: $0.98 | Profit: 86.05% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 21 at 3:53 AM
1ightning® Options Trade Alert (Actionable) | Buy $CMPX Dec 19 $5 Call | Enter: $0.52 Exit: $0.98 | Profit: 86.05% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 20 at 1:20 AM
1ightning® Options Trade Alert (Actionable) | Buy $CMPX Dec 19 $5 Call | Enter: $0.52 Exit: $0.98 | Profit: 86.05% ROI | https://1ightning.com
0 · Reply
Lexcol
Lexcol Nov. 19 at 3:44 PM
$CMPX
0 · Reply
Iightning
Iightning Nov. 19 at 9:29 AM
1ightning® Options Trade Alert (Actionable) | Buy $CMPX Dec 19 $5 Call | Enter: $0.52 Exit: $0.98 | Profit: 86.05% ROI | https://1ightning.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 16 at 11:09 PM
$CMPX $CNBS $COF $COHR $COIN
1 · Reply
Marvinvaca
Marvinvaca Nov. 15 at 12:00 PM
$CMPX https://youtu.be/P7TnHzJ6_20?si=Wq209zn6G416N8SW
0 · Reply
Lexcol
Lexcol Nov. 12 at 3:13 PM
$CMPX $OCGN
0 · Reply
Lexcol
Lexcol Nov. 12 at 1:59 PM
$CMPX 5$ today
0 · Reply
Lexcol
Lexcol Nov. 11 at 8:59 PM
$OCGN $CMPX
0 · Reply
Lexcol
Lexcol Nov. 11 at 2:49 PM
$CMPX New price target —> 30$
0 · Reply
Lexcol
Lexcol Nov. 10 at 8:58 PM
$CMPX Buy now Last occasion
0 · Reply
Lexcol
Lexcol Nov. 6 at 3:18 PM
$CMPX
0 · Reply
AlmaTobler366
AlmaTobler366 Nov. 5 at 4:55 PM
$CMPX trades lightly. AITX’s strategic partnerships and continued order flow demonstrate enduring momentum into year-end.
0 · Reply
JarvisFlow
JarvisFlow Nov. 5 at 1:47 PM
D. Boral Capital updates rating for Compass Therapeutics ( $CMPX ) to Buy, target set at 30.
0 · Reply
diegodempsey
diegodempsey Nov. 4 at 4:52 PM
$CMPX https://elite.finviz.com/news/216661/compass-therapeutics-presents-preclinical-data-on-ctx-10726-a-differentiated-pd-1-x-vegf-a-bispecific-antibody-at-the-40th-society-for-immunotherapy-of-cancer-sitc-annual-meeting
0 · Reply
Lexcol
Lexcol Oct. 30 at 1:46 PM
$CMPX News ESMO ??
0 · Reply
Lexcol
Lexcol Oct. 30 at 1:34 PM
$CMPX $OCGN Buy now !!!
0 · Reply
ChavezAAron
ChavezAAron Oct. 17 at 3:33 PM
$CMPX its a friday people trying to collect profits for the week...smart
0 · Reply
Johndoe456
Johndoe456 Oct. 15 at 8:15 PM
$CMPX
0 · Reply
Lexcol
Lexcol Oct. 15 at 4:04 PM
$CMPX Selllll
0 · Reply